Description

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C51H70N10O12S2—Nat Commun. 2023 Feb 21;14(1):962.|Research Square Print. 2022 Aug.|Basic Clin Pharmacol Toxicol. 2022 Jun 10.|Cell Mol Bioeng. 2022.|Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec.|J Pharm Biomed Anal. 11 December 2021, 114518.|J Pharm Biomed Anal. 2022: 115156.|J Pharm Sci. 2022 Oct 10;S0022-3549(22)00454-3.-[1]Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56.|[2]Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.–79517-01-4–1079.29–99.93–O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45.CC(O)=O–Inflammation/Immunology; Cardiovascular Disease; Endocrinology; Cancer–DMSO : 100 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)–Somatostatin Receptor—-GPCR/G Protein;Neuronal Signaling–Peptides